Vertero
Biotechnology company developing oral small-molecule therapeutics that target validated peripheral drivers of neurodegenerative diseases. Focus areas include discovery and validation of peripheral (gut/periphery) mechanisms that contribute to Parkinson’s disease and other neurodegenerative conditions, preclinical development through IND-enabling activities, and initiation of early-phase clinical trials.
Industries
biopharma
biotechnology
medical
pharmaceutical
Nr. of Employees
small (1-50)
Vertero
Products
VT-5006
First-in-class, gut-selective small molecule designed to engage a microbial amyloid target in the GI wall to reduce protein aggregation and inflammation implicated in Parkinson’s disease.
VT-6382
Small-molecule inhibitor targeting bile salt hydrolase, listed in early development for undisclosed indications.
VT-5006
First-in-class, gut-selective small molecule designed to engage a microbial amyloid target in the GI wall to reduce protein aggregation and inflammation implicated in Parkinson’s disease.
VT-6382
Small-molecule inhibitor targeting bile salt hydrolase, listed in early development for undisclosed indications.
Expertise Areas
- Peripheral-target discovery for neurodegenerative disease
- Parkinson’s disease-focused drug development
- Microbiome and microbial-amyloid biology
- Small-molecule medicinal chemistry
Key Technologies
- Metagenomics
- Animal disease models (in vivo functional assays)
- Small-molecule medicinal chemistry
- Pharmacokinetics and toxicology studies